Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (39209)	5/11/1999 10:06:00 PM
From: MikeD	Respond to of 120523

VMRX's TA could be telegraphing a future announcement regarding FDA approval of a cancer drug. From VMRX's Year End Report released March 31, 1999 we read: “In January, the FDA notified us that the Isolex® is approvable and we have since submitted all information requested by the agency and successfully completed their inspection process for our manufacturing facilities,” said L. William McIntosh, Nexell Therapeutics president and CEO. “With the pending approval of the Isolex®, we are on the verge of a watershed year, with increasing revenues and an unflagging commitment to research and development contributing to our long-term growth as a global cell therapy business.” MikeD